Price Alert

ADMA Biologics Inc. (ADMA)

NASDAQ: ADMA · Real-Time Price · USD

15.61

0.29 (1.89%)

At close: Sep 26, 2025, 3:59 PM

15.62

0.06%

After-hours: Sep 26, 2025, 07:57 PM EDT

ADMA Biologics Statistics

Share Statistics

ADMA Biologics has 238.63M shares outstanding. The number of shares has increased by 2.42% in one year.

Shares Outstanding	238.63M
Shares Change (YoY)	2.42%
Shares Change (QoQ)	0.47%
Owned by Institutions (%)	86.79%
Shares Floating	233.87M
Failed to Deliver (FTD) Shares	831
FTD / Avg. Volume	0.03%

Short Selling Information

The latest short interest is 15.74M, so 6.6% of the outstanding shares have been sold short.

Short Interest	15.74M
Short % of Shares Out	6.6%
Short % of Float	8.1%
Short Ratio (days to cover)	4.41

Valuation Ratios

The PE ratio is 20.22 and the forward PE ratio is 17.21. ADMA Biologics's PEG ratio is -0.03.

PE Ratio	20.22
Forward PE	17.21
PS Ratio	9.37
Forward PS	5.9
PB Ratio	11.45
P/FCF Ratio	36.31
PEG Ratio	-0.03

Financial Ratio History

Enterprise Valuation

ADMA Biologics has an Enterprise Value (EV) of 3.98B.

EV / Sales	9.32
EV / EBITDA	26.92
EV / EBIT	33.51
EV / FCF	36.12

Financial Position

The company has a current ratio of 5.97, with a Debt / Equity ratio of 0.24.

Current Ratio	5.97
Quick Ratio	2.9
Debt / Equity	0.24
Debt / EBITDA	0.56
Debt / FCF	0.75
Interest Coverage	9.98

Financial Efficiency

Return on Equity is 56.64% and Return on Invested Capital is 50.31%.

Return on Equity	56.64%
Return on Assets	40.45%
Return on Invested Capital	50.31%
Revenue Per Employee	$622.56K
Profits Per Employee	$288.57K
Employee Count	685
Asset Turnover	0.87
Inventory Turnover	1.22

Taxes

Income Tax	-71.96M
Effective Tax Rate	-57.24%

Stock Price Statistics

The stock price has increased by -19.49% in the last 52 weeks. The beta is 0.53, so ADMA Biologics's price volatility has been higher than the market average.

Beta	0.53
52-Week Price Change	-19.49%
50-Day Moving Average	17.01
200-Day Moving Average	18.3
Relative Strength Index (RSI)	40.65
Average Volume (20 Days)	3,113,488

Income Statement

In the last 12 months, ADMA Biologics had revenue of 426.45M and earned 197.67M in profits. Earnings per share was 0.85.

Revenue	426.45M
Gross Profit	219.55M
Operating Income	138.98M
Net Income	197.67M
EBITDA	147.69M
EBIT	139.64M
Earnings Per Share (EPS)	0.85

Full Income Statement

Balance Sheet

The company has 103.15M in cash and 82.12M in debt, giving a net cash position of 21.03M.

Cash & Cash Equivalents	103.15M
Total Debt	82.12M
Net Cash	21.03M
Retained Earnings	-308.58M
Total Assets	558.38M
Working Capital	324.62M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 118.67M and capital expenditures -8.57M, giving a free cash flow of 110.1M.

Operating Cash Flow	118.67M
Capital Expenditures	-8.57M
Free Cash Flow	110.1M
FCF Per Share	0.47

Full Cash Flow Statement

Margins

Gross margin is 51.48%, with operating and profit margins of 32.59% and 46.35%.

Gross Margin	51.48%
Operating Margin	32.59%
Pretax Margin	29.48%
Profit Margin	46.35%
EBITDA Margin	34.63%
EBIT Margin	32.59%
FCF Margin	25.82%

Dividends & Yields

ADMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	4.95%
FCF Yield	2.75%

Dividend Details

Analyst Forecast

The average price target for ADMA is $26, which is 66.6% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$26
Price Target Difference	66.6%
Analyst Consensus	Strong Buy
Analyst Count	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	5.35
Graham Upside	-65.73%

Scores

Altman Z-Score	15.94
Piotroski F-Score	6